Short term treatment of dermatophyte onychomycosis with terbinafine.
OBJECTIVE
To evaluate the effect of short term treatment with terbinafine on dermatophytosis.


METHODS
Multicentre, randomised, double blind placebo controlled trial of 250 mg/day terbinafine for 12 weeks in dermatophyte onychomycosis.


METHODS
Eight dermatology centres in the United Kingdom.


METHODS
112 patients (mean age 44, range 19-78), 99 with mycologically proved toenail infections and 13 with fingernail infections, of whom eight were subsequently excluded and 19 failed to complete the study.


METHODS
Terbinafine 250 mg daily or placebo for 12 weeks. Follow up for 36 weeks after stopping treatment.


METHODS
Mycological cure (negative results on microscopy and culture) and clinical cure at the end of follow up, adverse events, and biochemical and haematological variables at monthly intervals during treatment.


RESULTS
After follow up 82% (37/45) (95% confidence interval 68% to 92%) mycological cure and 69% clinical cure were recorded for evaluable patients treated with terbinafine for toenail infection and 71% (5/7) (30% to 96%) mycological cure and clinical cure for those treated for fingernail infection. The corresponding values for those treated with placebo were 12% (3% to 31%) mycological cure and no clinical cure for toenail infections and 33% (1% to 91%) mycological cure and no clinical cure for fingernail infections. On an intention to treat basis for toenail infections the figures were 73% (38/52) (58% to 85%) mycological cure for terbinafine compared with 6% (0% to 30%) for placebo (p less than 0.007). Two withdrawals were related to adverse events with terbinafine, and there were no significant abnormal laboratory test results.


CONCLUSIONS
12 weeks' terbinafine is effective and safe treatment for nail dermatophytosis.
Goodfield
M J
MJ
Department of Dermatology, General Infirmary, Leeds.
Andrew
L
L
Evans
E G
EG
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014009:Onychomycosis / Q000188:drug therapy*; D000077291:Terbinafine; D013997:Time Factors
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine